Press Release: New Aprotinin Insensitive ACT Test Receives FDA 510(k) Clearance
- Sienco®, Inc. is pleased to announce that our new aprotinin insenstive aiACT test is now available for domestic as well as export sale! This patented test is less affected by aprotinin than current celite or kaolin tests. It has been designed to be significantly unaffected by the presence of aprotinin in applications such as cardiopulmonary bypass. It is not intended for platelet function assessment.
The aiACT test's performance is comparable to the SonACT and kACT tests on both native whole blood and on heparinized blood. When in the presence of aprotinin, the aiACT test is the least sensitive to the presence of aprotinin, therefore best providing the user with an idea of the anti-coagulant effects of the heparin present and allowing the user to better manage patient care. It has been designed to provide results that are substantially equivalent to those of the SonACT and kACT tests so that institutions do not have to change hemostasis management protocols when using the aiACT test.
The aiACT test is available in boxes of 24 tests (P/N 800-0441) and 100 tests (P/N 800-0442). Call Sienco at 800-432-1624 or e-mail us at sienco@sienco.com to order your kit today!
This website by Small Planet Solutions, LLC
This page was last modified on 8/25/05
Copyright ©1996-2004 Sienco®, Inc. All rights reserved.
Sonoclot is a registered trademark of Sienco, Inc.
Sonoclot Analyzers are protected under US and foreign patents.